Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation

Lung cancer patients harbouring driver oncogene alterations are markedly responsive to molecular target agents, such as epidermal growth factor receptor (EGFR), tyrosine kinase inhibitor (TKI), and echinoderm microtubule-associated protein like 4 – anaplastic lymphoma kinase (EML4-ALK)-TKI. We encou...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kohei Fujita, Megumi Naka, Takanori Ito, Osamu Kanai, Koichi Maekawa, Koichi Nakatani, Tadashi Mio
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2021-01-01
Saila:	Respiratory Medicine Case Reports
Gaiak:	Alectinib EGFR mutation EML4-ALK rearrangement Osimertinib Lung adenocarcinoma
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2213007121000551
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!